NASDAQ — Healthcare: Manufacturing, Biotechnology: Biological Products (No Disgnostic Substances)
www.tscan.comThe clinical trial NCT06587828 is focused on metastatic solid tumors, investigating tumor antigen expression profiles and HLA (Human Leukocyte Antigen) genotypes through a multicenter screening study. No active treatment is given during this trial, as it aims to gather essential genetic information to inform potential participant referrals for interventional trials. The expected completion date for this trial is June 1, 2025, providing critical insights into patient eligibility for further clinical studies. TScan Therapeutics, Inc. is sponsoring the research, which has significant implications for advancing personalized cancer therapies.
Clinical Trial CompletionTScan Therapeutics, Inc. anticipates the completion of clinical trials for TSC-100 and TSC-101 on June 1, 2026. The study is focused on patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS) undergoing allogeneic peripheral blood stem transplantation. This Phase 1 trial aims to evaluate the safety and preliminary efficacy of the genetically engineered T cells in combination with standard of care. TSC-100 and TSC-101 target specific antigens and will be administered to HLA A*02:01 positive patients. The trial has enrolled 75 patients and is currently in the recruiting stage.
clinical trial completionTScan Therapeutics, Inc. is expected to complete a clinical trial involving customized autologous TCR-T cell therapies for patients with locally advanced or metastatic solid tumors by December 30, 2026. The trial, identified by Clinical Trial ID NCT05973487, is currently recruiting participants, with an expected enrollment of 840. Participants will undergo screening to determine eligibility based on genetic factors and tumor characteristics before being assigned to various treatment cohorts. The study aims to evaluate the efficacy of TCR-T therapies, with materials and combinations tailored to specific HLA types and tumor antigens, indicating a strategic focus on personalized medicine within cancer treatment.
Clinical Trial CompletionTScan Therapeutics, Inc. will complete a screening study on January 14, 2027, aimed at assessing tumor antigen expression profiles and HLA genotypes in patients with metastatic solid tumors. The trial, labeled as RECRUITING and initiated on June 26, 2023, will involve collecting samples including buccal swabs and archival tissue for analysis. Participants found to have specific HLA types will also provide saliva samples to evaluate HLA loss of heterozygosity. This study is a precursor to potential interventional trials for eligible participants.
Clinical Trial CompletionTScan Therapeutics, Inc. is set to complete its clinical trial, identified as NCT05812027, on January 14, 2027. The trial involves a multicenter study aimed at collecting samples to evaluate tumor antigen expression profiles, HLA genotypes, and HLA loss of heterozygosity in patients with metastatic solid tumors. Currently, the study is in the recruiting stage, with a target enrollment of 650 participants. No treatment interventions will occur during this screening phase; however, eligible participants may be referred to interventional trials based on the results. Results from this study could provide valuable insights for future therapeutic interventions related to tumor antigen targeting.
Clinical Trial CompletionTScan Therapeutics, Inc. is set to complete its long-term follow-up (LTFU) study of TCR-T products on September 1, 2040. This study, identified by clinical trial NCT06976736, will involve the monitoring of participants for safety and efficacy over a 15-year period after they have completed the TSCAN-001 interventional trial. No additional study drug will be administered during the follow-up, but participants may receive other cancer treatments as needed. The expected enrollment is 1,000 participants, although the study is currently not yet recruiting.
Clinical Trial Completion